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Background. Invasive fungal infections (IFIs) are life-threatening complications in patients with hemato-
oncological malignancies, and early diagnosis is crucial for outcome. The compound 1,3-b-D-glucan (BG), a cell
wall component of most fungal species, can be detected in blood during IFI. Four commercial BG antigenemia assays
are available (Fungitell, Fungitec-G, Wako, and Maruha). This meta-analysis from the Third European Conference
on Infections in Leukemia (ECIL-3) assessed the performance of BG assays for the diagnosis of IFI in hemato-
oncological patients.
Methods. Studies reporting the performance of BG antigenemia assays for the diagnosis of IFI (European
Organization for Research and Treatment of Cancer and Mycoses Study Group criteria) in hemato-oncological
patients were identified. The analysis was focused on high-quality cohort studies with exclusion of case-control
studies. Meta-analysis was performed by conventional meta-analytical pooling and bivariate analysis.
Results. Six cohort studies were included (1771 adult patients with 414 IFIs of which 215 were proven or
probable). Similar performance was observed among the different BG assays. For the cutoff recommended by the
manufacturer, the diagnostic performance of the BG assay in proven or probable IFI was better with 2 consecutive
positive test results (diagnostic odds ratio for 2 consecutive vs one single positive results, 111.8 [95% confidence
interval {CI}, 38.6–324.1] vs 16.3 [95% CI, 6.5–40.8], respectively; heterogeneity index for 2 consecutive vs one
single positive results, 0% vs 72.6%, respectively). For 2 consecutive tests, sensitivity and specificity were 49.6%
(95% CI, 34.0%–65.3%) and 98.9% (95% CI, 97.4%–99.5%), respectively. Estimated positive and negative
predictive values for an IFI prevalence of 10% were 83.5% and 94.6%, respectively.
Conclusions. Different BG assays have similar accuracy for the diagnosis of IFI in hemato-oncological patients.
Two consecutive positive antigenemia assays have very high specificity, positive predictive value, and negative
predictive value. Because sensitivity is low, the test needs to be combined with clinical, radiological, and
microbiological findings.
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Early recognition and treatment of life-threatening invasive
fungal infections (IFIs) in patients with hemato-oncological
malignancies are crucial for positive outcomes [1]. Uncertain
detection of IFI, due to limited performance of cultures and
imaging, results in prolonged empirical antifungal therapy
[2, 3]. New tools are thus needed for early diagnosis and
prompt, targeted therapy.
The glucose polymer 1,3-b-D-glucan (BG), a major cell wall
component of most fungal species (with exception of zy-
gomycetes and Cryptococcus spp.), is released in blood and
tissues in the course of IFI. Measurement of BG levels is based
on activation by BG of factor G of the coagulation cascade in
the amebocyte lysate from the horseshoe crab, which leads to
quantifiable transformation of a chromogenic substrate [4]. BG
assays with different thresholds of detection that use reagents
from different horseshoe crab species are commercially avail-
able: Limulus polyphemus from North America and Tachypleus
tridentatus from Japan. BG has been evaluated in case-control
studies (patients with proven or probable IFI vs healthy con-
trols or distinct patient populations at low risk of IFI) with
50%–90% sensitivity and 70%–100% specificity [5–8]. Moni-
toring BG antigenemia has also been assessed in prospective
cohorts of homogeneous populations at high risk of IFI [9–11],
which better reflect the real performance of the test.
Recently, the BG test has been included in the revised Euro-
pean Organization for Research and Treatment of Cancer and
Mycoses Study Group (EORTC-MSG) consensus definitions of
probable IFI [2]. However, no recommendations have been
formulated regarding the use of different assays, timing and
number of measurements, and criteria of positivity.
This study was conducted on behalf of the Third European
Conference on Infections in Leukemia (ECIL-3; Juan-les-Pins,
France, September 2009). The objective was to assess the
performance of BG assays for diagnosis of IFI in hemato-on-
cological patients by a systematic literature review and meta-
analysis of cohort studies.
METHODS
Search Strategy and Selection Criteria
A systematic search of the literature was performed using the fol-
lowing sources from inception through the end of December 2009:
Medline database through PubMed (http://www.ncbi.nlm.nih.
gov/pubmed), Embase through Ovid, and Scopus (http://www.
scopus.com/home.url). The following keywords were used: glucan,
beta-glucan, fungal infection, mycoses, aspergillosis, Aspergillus,
candidiasis, and Candida. The following syntax was used: ‘‘glucan’’
OR ‘‘beta-glucan’’ AND ‘‘fungal infections’’ OR ‘‘mycoses,’’ AND/
OR ‘‘Aspergillus’’ OR ‘‘aspergillosis,’’ AND/OR ‘‘candidiasis’’ OR
‘‘Candida.’’ This search was completed by the consultation of ab-
stracts from international infectious diseases or hemato-oncology
meetings and reviews (2005–2009). No language restriction was
applied. The abstracts identified through the above search
strategy were screened by 3 authors (F. L., M. C., and O. M.).
Full text of potentially relevant publications of clinical studies
reporting measurement of BG antigenemia for the diagnosis of
IFI was analyzed on the basis of the following inclusion criteria:
(1) The test used was a commercially available BG assay with
evaluation of the cutoff value for positivity recommended by the
manufacturer: Fungitell (formerly Glucatell; Associates of Cape
Cod, East Falmouth, MA), Fungitec-G (Seikagaku, Kogyo,
Tokyo, Japan), Wako turbidimetric assay (Wako Pure Chem-
ical Industries, Tokyo, Japan), and Maruha colorimetric assay
(Maruha-Nichiro Foods, Tokyo, Japan). (2) The study pop-
ulation was mainly (.50%) composed of adult or pediatric
hemato-oncological patients at risk of IFI (prolonged neu-
tropenia after myelosuppressive chemotherapy for acute leu-
kemia or hematopoietic stem cell transplantation). (3) The
EORTC-MSG criteria [2, 12] were used as a reference standard
for classification of IFI, invasive candidiasis (IC), and invasive
aspergillosis (IA) as proven, probable, or possible, in-
dependently of BG test results (2002 criteria were used in all
studies with the exception of 1 study that applied 2008 criteria
after exclusion of BG test results). Studies conducted before
2002 could be included if the reported information allowed post
hoc classification of IFI according to EORTC-MSG criteria.
Studies reporting the use of BG in patients with Cryptococcus
spp. or Pneumocystis jirovecii infections only were excluded,
because these fungal pathogens are beyond the scope of this
analysis. (4) Data on true-positive, true-negative, false-positive,
and false-negative results of the BG test were reported sepa-
rately or could be calculated from the manuscript. (5) BG
measurements were performed in a homogenous cohort of
patients at risk of IFI according to a monitoring strategy or
based on clinical suspicion of IFI (case-control studies com-
paring IFI with healthy controls or controls from distinct pa-
tient populations at low risk of IFI were excluded). If needed,
corresponding authors were contacted for retrieval of com-
plementary information. Agreement of 3 authors (F. L., M. C.,
and O. M.) on the above criteria was required for inclusion in
the analysis.
Quality of included studies was assessed by 3 authors (F. L., M.
C., and C. M.) according to recommendations of Standards for
Reporting of Diagnostic Accuracy [13] by use of the Quality As-
sessment of Diagnostic Accuracy Studies (QUADAS) tool based
on 14 items (Figure 2) specifically developed for assessing quality
of studies on diagnostic tests [14]. Each item was scored as ‘‘yes,’’
‘‘no,’’ or ‘‘unclear,’’ and agreement of 3 authors was required.
1,3-b-D-Glucan Data and Statistical Analyses
Raw data of positive and negative BG test results were extracted
for all cutoffs and evaluated for the following diagnostic criteria:
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(1) proven or probable IFI according to EORTC-MSG clas-
sification [2, 12] versus no IFI, possible IFI being excluded;
(2) proven, probable, or possible IFI versus no IFI; (3) proven
or probable IC versus no IFI, other IFI being excluded; and
(4) proven or probable IA versus no IFI, other IFI being ex-
cluded. Criteria defining a positive test were as follows:
(1) a single value above a given cutoff (criterion A), and (2) 2
consecutive values above a given cutoff (criterion B). Analyses
of receiver operating characteristic (ROC) curves were performed
for studies reporting results for different BG cutoffs.
For meta-analysis, 2 distinct approaches were used: (1) a con-
ventional meta-analytical method after logit transformation
(based on the inverse variance method for weight evaluation)
[15], and (2) a bivariate random effects approach, which pre-
serves the bidimensional nature of sensitivity and specificity
data [16, 17]. Cumulative estimates of sensitivity, specificity,
positive and negative likelihood ratios, and diagnostic odds
ratios (DORs) were calculated. The DOR ([true positives 3
true negatives]/[false positives 3 false negatives]) was adopted
as a diagnostic accuracy index that simultaneously integrates
sensitivity and specificity. The hierarchical summary ROC
(hsROC) curvemethod was used [18] in order tomodel the trade-
off between sensitivity and specificity for various cutoffs. The
hsROC curve method overcomes some limitations of the tradi-
tional summary ROC curve procedure indicated by Moses and
Littenberg [19] and is closely related to bivariate random-effects
meta-analysis. Heterogeneity was assessed by visual inspection of
forest plots and hsROC plots of raw data. Moreover, heterogeneity
was formally assessed by a test of inconsistency (I2). Because some
studies explored several BG cutoffs, only data on cutoffs recom-
mended by the manufacturers for each single assay were included
in meta-analysis (Fungitell cutoff, 60–80 pg/mL; Fungitec-G
cutoff, 20 pg/mL; Wako and Maruha cutoff, 11 pg/mL).
Positive and negative predictive values of BGwere determined
over a wide range of prevalence of IFI by use of the Bayes’
theorem with summary of sensitivity and specificity data. The
following statistic software were used: RevMan 5 (http://ims.
cochrane.org/revman/about-revman-5), MetaDisc (http://www.
hrc.es/investigacion/metadisc_en.htm), and Stata 11 (http://
www.stata.com/).
RESULTS
Study Selection
A total of 1076 studies were identified by systematic review of
the literature: 1036 were excluded because they did not address
the study question or did not fulfill the inclusions criteria, and
40 were reviewed as full papers (Figure 1). Ten cohort studies
were identified, of which 4 did not meet the inclusion criteria:
2 were performed in populations other than hemato-oncological
patients [20, 21], and 2 evaluated a single cutoff value different
from that recommended by themanufacturer in a limited number
of patients [22, 23].
The characteristics of the 6 cohort studies [9–11, 24–26]
fulfilling the inclusion criteria are listed in Table 1. The BG levels
were measured in blood samples on the basis of a screening
strategy (once or twice weekly) in 5 studies. In 1 study [26], all
patients who had at least 1 BG measurement for suspected IFI
were enrolled. Five studies included exclusively patients with
hematological malignancies at high risk of IFI (prolonged
neutropenia after myelosuppressive chemotherapy or allogeneic
hematopoietic stem cell transplantation), whereas the pop-
ulation was mixed (60% hemato-oncological patients) in the
remaining study [26]. The individual quality assessments of
each study, as well as the summary for each item across all the
included studies, are presented in Figure 2.
A total of 1771 patients were analyzed, including 414 episodes
of IFI, of whom 215 (52%) were classified as proven or probable
according to EORTC-MSG criteria: 90 (42%) had IA, 80 (37%)
had IC, and 45 (21%) had IFI attributed to other fungi (including
mixed episodes); (Table 1).
The performance of the BG assay for the diagnosis proven or
probable IFI could be assessed in all but 1 study [9], which
reported only sensitivity and specificity for proven, probable, or
possible IFI. Performance for different cutoffs was assessed in
4 studies [9, 11, 25, 26]. Different numbers of test results above
a given cutoff to define positivity (single test, criterion A;
$2 consecutive tests, criterion B) were assessed in 4 studies
[9–11, 25]. The 6 primary publications generated several
comparisons to the reference standard: 15 for the Fungitell
assay (cutoff, 31–500 pg/mL), 18 for the Wako and Maruha
assays (cutoff, 2–11 pg/mL), and 1 for the Fungitec-G assay
(cutoff, 20 pg/mL).
ROC Curve Analyses
The ROC curve analyses of studies reporting different cutoffs of
positivity in proven or probable IFI are shown in Figure 3. For
the Wako andMaruha assays, cutoffs of 2–11 pg/mL were tested
in 2 studies [11, 25]. The areas under the curves (AUCs) ob-
tained by pooling the results of both studies for criteria A and B
did not differ considerably (0.84 and 0.88, respectively). For
the Fungitell assay, different cutoffs were evaluated in 1 study
(31–500 pg/mL) [26]. Analysis was possible only for criterion A:
the AUC for this criterion was similar to that obtained with the
Wako andMaruha assays (0.80 vs 0.84, respectively). ROC curve
analysis was not possible for the Fungitec-G assay because
data were lacking on the diagnostic performance of different BG
cutoffs. On the basis of the ROCs, the optimal cutoffs (ie, the
shortest distance between the point of a given cutoff on the ROC
curve and the left upper corner of the graph representing 100%
sensitivity and 100% specificity) were as follows: 5 pg/mL
(sensitivity, 76%; specificity, 77%) for criterion A and 3 pg/mL
b-Glucan in Invasive Fungal Infection d CID 2012:54 (1 March) d 635
(sensitivity, 85%; specificity, 74%) for criterion B with the
Wako and Maruha assays, and 60 pg/mL (sensitivity, 70%;
specificity, 81%) for criterion A with the Fungitell assay.
Meta-Analysis
For the meta-analysis, data obtained with the cutoff recom-
mended by the manufacturer (see ‘‘Methods’’) were selected for
each study. Results of the bivariate analysis for criterion A are
shown in Figure 4 (not performed for criterion B because of
lacking data). Figure 5 shows the forest plot of the DOR ob-
tained by meta-analytical pooling. For the diagnosis of proven
or probable IFI, a higher DOR was obtained for criterion B
when compared with criterion A (111.8 vs 16.3, respectively).
Heterogeneity was absent for criterion B, but it was substantial
for criterion A (I2, 0% and 71.6 %, respectively). The overall
performance of the BG test was lower for proven, probable, or
possible IFI. Results of cumulative estimates of DOR, sensitivity,
specificity, and positive and negative likelihood ratios obtained
by both methods (bivariate analysis andmeta-analytical pooling)
are shown in Table 2.
Data on the performance of BG for the diagnosis of proven
or probable IA and IC were reported separately in 4 studies
[10, 11, 24, 25] and 2 studies [10, 11], respectively. The pooled
DOR, sensitivity, and specificity in IA and IC were as follows:
(1) criterion A, 79.1 (21.0–298.6), 0.57 (0.33–0.83), and 0.97
(0.96–0.98) in IA and 177.6 (16.1–1954.2), 0.73 (0.57–0.85),
and 0.97 (0.95–0.98) in IC; (2) criterion B, 24.1 (6.8–84.5), 0.46
(0.21–0.73), and 0.97 (0.95–0.98) in IA, and 124.7 (33.6–462.1),
0.75 (0.42–0.94), and 0.97 (0.96–0.98) in IC.
The estimated positive and negative predictive values of the
BG test for the diagnosis of proven or probable IFI according
to the IFI prevalence are shown in Figure 6. The median IFI
prevalence in the analyzed studies was 10% (range, 7%–27%),
which resulted in an estimated positive predictive value of 46.1%
and negative predictive value of 97.1% for criterion A, and
a positive predictive value of 83.5% and negative predictive
value of 94.6 % for criterion B.
DISCUSSION
This ECIL-3 meta-analysis of the diagnostic performance of BG
antigenemia in IFI was focused on adult hemato-oncological
patients at high risk of IFI in whom preemptive antifungal
strategies guided by biological markers are being intensively
Figure 1. Flowchart of study selection. Abbreviations: BG, b-glucan assay; EORTC-MSG, European Organization for Research and Treatment of Cancer
and Mycoses Study Group; ICU, intensive care unit; IFI, invasive fungal infection; SOT, solid-organ transplant recipient.
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Table 1. Characteristics of Cohort Studies Assessing the Performance of b-Glucan Assays for the Diagnosis of Invasive Fungal Infection in Patients With Hematological
Malignancies
Study Reference BG Assay
Biological
Sample Study Design
Frequency of
BG Screening Study Population
Antifungal
Therapy
No. of Patients
Total
Any
IFI
Proven or
Probable
IFI
Invasive
Candidiasis
Invasive
Aspergillosis
Other
IFI
Odabasi et al
(2004) [10]
Fungitell (ACC,
United States)
Serum Prospective,
consecutive
Twice per week Adults (100% with H,
no aHSCT)
Prophylaxis (all) 283 53 20 11 3 6a
Ellis et al
(2008) [9]
Fungitell (ACC,
United States)
Serum Prospective,
consecutive
Every 2 days Adults (100% with H,
no aHSCT)
Empiricalb (all) 80 38 26 12 14 0
Koo et al
(2009) [26]
Fungitell (ACC,
United States)
Serum Retrospective,
consecutive
No screeningc Adults (60% with H,
23% with aHSCT)
NA 871 209d 112 41 32 39e
Kami et al
(2000) [24]
Fungitec-G
(Seikagaku,
Japan)
Plasma Prospective,
consecutive
Once per week Adults (100% with H,
30% with aHSCT)
Prophylaxis (all) 215 30 16 0 16 0
Kawazu et al
(2004) [25]
Wako (Japan) Plasma Prospective,
consecutive
Once per week Adults (100% with H,
38% with aHSCT)
NA 149 24 11 0 11 0
Senn et al
(2008) [11]
Maruha and Wako
(Japan)
Serum Prospective,
consecutive
Twice per week Adults (100% with H,
no aHSCT)
Prophylaxis
(22% of
patients)
173 60 30 16 14 0
Abbreviations: ACC, Associates of Cape Cod (see ‘‘Methods’’); aHSCT, allogeneic hematopoietic stem cell transplantation; BG, 1,3-b-D-glucan; H, hematological malignancies; IFI, invasive fungal infection; NA, data not
available.
a Other molds, 5 patients; mixed species, 1 patient.
b All patients had persistent neutropenic fever of unknown origin for .3 days.
c The first BG measurement performed according to clinical suspicion of IFI was used for analysis.
d IFI occurring within 1 week after initial BG testing.
e Pneumocystis jirovecii, 14 patients; zygomycetes, 4 patients; other molds or yeasts, 16 patients; mixed species, 3 patients; dimorphic fungi, 2 patients.
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investigated. Data on 1771 patients, including 414 IFI cases
(215 proven or probable), were extracted from 6 high-quality
cohort studies fulfilling strict criteria for patient enrollment,
data collection, and data analysis. In particular, the selection of
patients with homogenous underlying risk profiles makes them
highly representative of the real clinical conditions in the
hemato-oncological setting. Because of their implications for
BG use in these patients, some findings of this meta-analysis
A B
Figure 2. Methodological quality graph summary of all included studies with the authors' appreciation about each methodological quality item
(QUADAS tool) according to the recommendations of the Standards for Reporting of Diagnostic Accuracy. Studies are identified by first author and year.
Quality assessment of each individual study by the 14 items (A), and summary of quality assessment for each of the 14 items across all the included
studies (B ).
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Figure 3. Receiver operating characteristic (ROC) curve analyses of b-glucan (BG) assays for the diagnosis of invasive fungal infections (IFIs; European
Organization for Research and Treatment of Cancer and Mycoses Study Group criteria). Analyses have been performed for the diagnostic standard proven
or probable IFI for 2 different types of BG assay (Fungitell and Wako/Maruha). Analysis for each test is shown according to the number of BG test results
above a given cutoff: 1 single positive value (criterion A) and 2 positive consecutive values (criterion B). Different cutoffs were assessed in 3 studies: Koo
et al (2009) [26] for Fungitell (analysis for criterion B was not possible for this study because of lacking data), Senn et al (2008) [11] for Wako/Maruha, and
Kawazu et al (2004) [25] for Wako/Maruha. Each point of the ROC is labeled by the corresponding cutoff (pg/mL).
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should be highlighted. First, similar diagnostic accuracy was
found among commercial BG assays based on different reagents
(L. polyphemus and T. tridentatus horseshoe crabs). Second,
higher diagnostic performance and better homogeneity of test
results were found for 2 consecutive positive BG antigenemia
assays than for a single one; although derived from a limited
number of studies that used different screening strategies, this
finding is clinically relevant because no recommendation re-
garding the number of measurements required for defining
a BG test result as positive (1 single vs 2 consecutive positive
antigenemia assays) has been formulated so far. Third, re-
gardless of the criteria for positivity and despite very high
negative predictive values, the sensitivity of BG remains low;
this implies that a negative result is not reliable to rule out this
life-threatening disease and that therapeutic decisions should
only be based on combining BG with classical clinical, radio-
logical, and microbiological findings. Fourth, very high speci-
ficity (99%) and positive predictive values of 2 consecutive
positive BG antigenemia assays suggest that such a finding is
sufficient per se to rule in diagnosis of probable IFI according
to EORTC-MSG criteria and to preemptively start antifungal
therapy. Fifth, the present meta-analysis shows that important
issues remain unanswered. Due to differences in screening
strategies (BG monitoring during the period at risk for IFI vs
punctual testing based on clinically driven suspicion of IFI) and
in frequencies of BG testing (once to thrice weekly), optimal
timing of blood sampling and time interval between 2 BG
measurements to confirm a positive result could not be as-
sessed. Lack of data also preclude drawing conclusions on the
optimal cutoff for BG positivity. The ROC curve analyses
suggested a lower threshold than that recommended for the
Fungitell assay (60 vs 80 pg/mL) and the Wako and Maruha
assays (3–5 vs 11 pg/mL). However, these findings were derived
from limited data in few studies. The meta-analysis was thus
based on cutoffs recommended by manufacturers to avoid bias
due to unreliable accuracy of extreme values. Data on perfor-
mance of BG in IFI due to specific fungal pathogens are also
unclear or lacking. Despite apparent superiority of BG per-
formance in IC compared with that in IA, this result should be
interpreted cautiously because separate analysis in IC was
available from only 2 studies. The low number of IFI due to less
common fungal pathogens did not allow any specific subgroup
analysis.
A recent meta-analysis on BG performance for the diagnosis
of IFI pooled hemato-oncological patients, nonhematological
patients in the intensive care unit, and transplant recipients from
case-control and cohort studies. With important data hetero-
geneity, the sensitivity and specificity of a single positive BG
value was 76.8% and 85.3%, respectively [27]. The broad mix of
both cases controls and study designs could explain the better
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Figure 4. Bivariate analysis of the sensitivity and specificity of b-glucan (BG) assays for the diagnosis of invasive fungal infection (IFI; European
Organization for Research and Treatment of Cancer and Mycoses Study Group criteria) using the cutoffs recommended by the manufacturer (Fungitell
cutoff, 60–80 pg/mL; Fungitec-G cutoff, 20 pg/mL; Wako and Maruha cutoff, 11 pg/mL). A, Diagnostic standard proven or probable IFI with a single value
above the recommended cutoff (criterion A). B, Diagnostic standard proven, probable, or possible IFI with a single value above the recommended cutoff
(criterion A). The bivariate analysis presents studies as sensitivity and specificity data, which are identified by the coordinates of corresponding points in
sensitivity-specificity space. Ellipses indicate the bidimensional limits of confidence of sensitivity and specificity for each diagnostic criterion: dashed
line, 95% confidence area; dotted line, 95% prediction area. The hierarchical summary ROC (hsROC) curve is a quasi-equivalent summary ROC that is
coherent with the bivariate estimate. The analysis was not possible for criterion B (2 consecutive values above the recommended cutoff) because of
lacking data. Studies are identified by first author and year. Solid line, hsROC curve; square, central estimate.
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sensitivity and lower specificity compared with the present meta-
analysis strictly derived from cohorts of hemato-oncological
patients. Moreover, diagnostic performance was not assessed for
2 consecutive positive BG values.
Some intrinsic limitations due to the design of the included
studies need to be discussed. Based on quality assessment (using
the QUADAS tool), lack of precision on timing of BG meas-
urements referring to time of diagnosis of IFI according to
EORTC-MSG criteria was observed. In the majority of studies,
information on blinded interpretation of BG test results, re-
porting of noninterpretable BG test results, and explanation
of data withdrawals from analysis were unclear or lacking. In
addition, most studies did not report data on potential causes
of false-negative BG test results (eg, antifungal prophylaxis or
therapy at time of BG measurement, and type, location, and
severity of IFI) or false-positive results (eg, concomitant b-lactam
therapy; blood transfusions, blood-derived products, or he-
modialysis or hemofiltration; and bacterial coinfections). Lack
of data on specific types of patients (eg, allogeneic hematopoietic
stem cell transplant recipients vs other hemato-oncological
patients, patients receiving vs those not receiving antifungal
agents, neutropenic vs nonneutropenic patients, and patients
with vs those without gastrointestinal tract mucositis or graft-
vs-host disease) did not allow differentiated subgroup analyses.
None of the included studies reported data from pediatric
populations, in whom higher BG levels and lower specificity
NOTE: Weights are from random effects analysis
proven/probable, criterion A
Kami (2000)
Koo (2009)
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Kawazu (2004)
Senn (2008)
Subtotal  (I2 = 71.6%, P = .007)
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Wako/Maruha
Fungitell
Fungitell
Wako/Maruha
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Figure 5. Forest plot of diagnostic odds ratios (DORs) of b-glucan (BG) assays for the diagnosis of invasive fungal infections (IFIs; European
Organization for Research and Treatment of Cancer and Mycoses Study Group criteria) using the cutoffs recommended by the manufacturer (Fungitell
cutoff, 60–80 pg/mL; Fungitec-G cutoff, 20 pg/mL; Wako and Maruha cutoff, 11 pg/mL). Analyses were performed for the diagnostic standards proven or
probable IFI, and proven, probable, or possible IFI. Analysis for each test is shown according to the number of BG test results above the recommended
cutoff: 1 single positive value (criterion A) and 2 positive consecutive values (criterion B). The sizes of the squares are proportional to the weights of the
studies. Studies are identified by first author and year. Abbreviations: CI, confidence interval.
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have been suggested in small series [28, 29]. Moreover, only
data on performance of the BG test in blood samples are
available. Its diagnostic utility in other biological samples
(eg, bronchoalveolar lavage fluid, cerebrospinal fluid, and
tissue biopsy specimens) remains unknown.
The BG test can be used as diagnostic tool for the detection of
a broad spectrum of fungal pathogens. Compared with other
fungal markers specific for Aspergillus spp. (galactomannan) or
Candida spp. (mannan and antimannan), BG seems to have
lower sensitivity and similar specificity [30, 31]. However, the
few studies comparing or combining BG with other fungal
markers do not allow any conclusion about the superiority
of a single test or combination of tests [5, 23, 25]. Prospective
randomized interventional studies assessing the role of a screen-
ing strategy that includes single or multiple fungal markers in
combination with clinical, radiological, and microbiological
findings for starting preemptive antifungal therapy are scarce
[32–34]. Such studies may better define the clinical validity and
cost effectiveness of a BG-driven strategy for management of
IFI in hemato-oncological patients.
In conclusion, commercially available BG assays display
similar accuracies in hemato-oncological patients at high risk
of IFI, with the highest diagnostic performance achieved with
the use of 2 consecutive positive BG values. Despite the high
negative predictive value, due to low sensitivity, a negative BG
antigenemia assay should be interpreted with caution and only
in combination with clinical, radiological, and microbiological
findings. However, remarkably high specificity and positive
Table 2. Cumulative Estimates of Diagnostic Odds Ratio, Sensitivity, Specificity, and Positive and Negative Likelihood Ratios of the
b-Glucan Assay for the Diagnosis of Invasive Fungal Infections
Criterion for Positivity,
Analysisa DOR (95% CI) Sensitivity, %(95% CI) Specificity, %(95% CI) PLR (95% CI) NLR (95% CI)
Proven or probable IFI
Criterion A
Bivariate 24.4 (5.8–103.2) 70.2 (47.0–86.2) 91.2 (83.1–95.6) 7.99 (3.45–18.51) 0.33 (0.16–0.67)
MA pooling 16.3 (6.5–40.8) 61.5 (48.3–73.2) 90.8 (83.4–95.1) 7.30 (3.59–14.84) 0.46 (0.34–0.60)
Criterion B
Bivariate NA NA NA NA NA
MA pooling 111.8 (38.6–324.1) 49.6 (34.0–65.3) 98.9 (97.4–99.5) 50.10 (20.25–123.97) 0.53 (0.40–0.71)
Proven, probable, or
possible IFI
Criterion A
Bivariate 11.4 (4.6–28.3) 61.3 (32.3–84.1) 87.8 (67.7–96.1) 5.02 (2.23–11.33) 0.44 (0.23–0.83)
MA pooling 11.5 (3.9–34.1) 59.4 (34.9–80.0) 87.3 (68.6–95.6) 4.38 (2.00–9.59) 0.52 (0.35–0.76)
Criterion B
Bivariate NA NA NA NA NA
MA pooling 32.3 (15.3–68.1) 44.1 (20.1–71.2) 97.5 (81.5–99.7) 14.98 (3.60–62.36) 0.64 (0.49–0.83)
Abbreviations: BG, 1,3-b-D-glucan; CI, confidence interval; DOR, diagnostic odds ratio; IFI, invasive fungal infection; MA, meta-analytical; NA, not available;
NLR, negative likelihood ratio; PLR, positive likelihood ratio.
a According to the European Organization for Research and Treatment of Cancer and Mycoses Study Group criteria: criterion A of IFI, positivity defined by a single
BG value above the recommended cutoff; criterion B, positivity defined by 2 consecutive BG values above the recommended cutoff. The cumulative estimates were
calculated using data for the cutoff recommended by the manufacturer (Fungitell cutoff, 60–80 pg/mL; Fungitec-G cutoff, 20 pg/mL; Wako and Maruha cutoff,
11 pg/mL) of each study. Diagnostic accuracy indices were evaluated by bivariate analysis and meta-analytical pooling (random effects according to DerSimonian and
Laird [36]; weights by the inverse variance method) for criterion A and criterion B. The bivariate analysis was not possible for criterion B due to lacking data.
Figure 6. Estimated positive predictive values (PPVs) and negative
predictive values (NPVs) of b-glucan (BG) assays for the diagnosis of proven
or probable invasive fungal infections (IFIs; European Organization for
Research and Treatment of Cancer and Mycoses Study Group criteria) in
patients with hemato-oncological malignancies, using the cutoffs
recommended by the manufacturer (Fungitell cutoff, 60–80 pg/mL;
Fungitec-G cutoff, 20 pg/mL; Wako and Maruha cutoff, 11 pg/mL; Bayesian
approach). The x-axis is the range of prevalence of IFI (0%–100%); the y-axis
is PPV and NPV (%). The analysis for each test is shown according to the
number of BG test results above the recommended cutoff: 1 single positive
value (criterion A) and 2 positive consecutive values (criterion B).
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predictive values of 2 consecutive positive BG antigenemia
assays make this test a reliable diagnostic marker of IFI. These
findings are consistent with the B-II grading of recommenda-
tion and level of evidence proposed by the ECIL-3 expert panel
for the use of BG in hemato-oncological patients [35]. Assess-
ment of the optimal BG cutoff, best timing of BGmeasurements,
and efficiency of combining BG with other fungal markers
needs specifically designed clinical investigations.
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